PETQ PetIQ, Inc. Class A

PetIQ, Inc. develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements. The company provides its products primarily under the VetIQ, PetAction Plus, Advecta, PetLock Plus, and TruProfen brands. It sells its products through distributors as well as through retail stores, including approximately 40,000 retail pharmacy locations. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho. The company has class B common shares outstanding that are privately held.

$39.90  +0.50 (1.27%)
As of 05/13/2021 15:59:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  07/21/2017
Outstanding shares:  28,372,028
Average volume:  492,364
Market cap:   $1,192,476,337
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    71639T106
ISIN:        US71639T1060
Sedol:      BDH65C8
Valuation   (See tab for details)
PE ratio:   -16.15
PB ratio:   4.72
PS ratio:   1.41
Return on equity:   -29.53%
Net income %:   -8.65%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy